Sign In
Buy ENLV
$2.09
+0.140 (+7.18%)
At Close: Jul 31, 2026
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
08:00am, Thursday, 30'th Jul 2026
As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
08:00am, Wednesday, 29'th Jul 2026
Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including
Enlivex Announces $400,000,000 Private Placement
08:00am, Tuesday, 28'th Jul 2026
Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announ
Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)
01:15am, Wednesday, 22'nd Jul 2026
Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) and Korro Bio (NASDAQ: KRRO - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two bu
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
08:00am, Monday, 20'th Jul 2026
Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an up
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
01:01pm, Monday, 13'th Jul 2026
Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Monday, 13'th Jul 2026
The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in oversold territory now.
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
08:00am, Monday, 13'th Jul 2026
Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
08:00am, Tuesday, 07'th Jul 2026
Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split
Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “ Enlivex ” or the “ Company ” ), a quality longevity company powered by a prediction markets treasury, today a
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
08:45am, Monday, 22'nd Jun 2026
Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an up
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
08:00am, Monday, 15'th Jun 2026
Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
08:00am, Tuesday, 02'nd Jun 2026
As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors Nes-Ziona, Israel, June 02, 2026 (GLOBE
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
08:00am, Monday, 01'st Jun 2026
The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis Nes-Ziona, Israel, June 01, 2
As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion. Separately, the Rain Foundation recently announced the appointment of five industry leade
